Trial Profile
DUOdopa/Duopa in Patients With Advanced Parkinson's Disease (PD) - a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Aug 2022
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms DUOGLOBE
- Sponsors AbbVie
- 28 Jun 2022 Results presented at the 8th Congress of the European Academy of Neurology
- 26 Apr 2022 Results of a final analysis assessed the long term effectiveness and safety of levodopa-carbidopa intestinal gel during routine clinical practice in patients with advanced Parkinson's disease presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 26 Apr 2022 Results of a post hoc analysis assessed the effect of baseline disease severity on long-term effectiveness and safety of levodopa-carbidopa intestinal gel treatment in routine clinical practice presented at the 74th Annual Meeting of the American Academy of Neurology 2022